AlzeCure Scores a Major Win With Lilly Alzheimer's Deal

Eli Lilly has just announced a collaboration and licensing agreement with Swedish biotech company AlzeCure Pharma for the global rights to Alzstatin ACD680, an experimental Alzheimer’s treatment.

Under the terms of the agreement, AlzeCure will receive a $10 million upfront payment, potential development and commercial milestone payments, and tiered royalties on future sales. If all milestones are achieved, the total value of the deal could exceed $1 billion, excluding royalties.

So what exactly is Lilly buying?

Alzstatin ACD680 belongs to a class of drugs known as gamma-secretase modulators. The compound is designed to reduce production of the amyloid-beta protein Aβ42, which is believed to play a central role in the formation of the amyloid plaques found in Alzheimer’s patients.

At the same time, the drug aims to increase production of shorter amyloid proteins, Aβ37 and Aβ38, which may help reduce plaque formation and aggregation.

To be sure, AlzeCure is far more than a one-asset company.

In addition to its Alzstatin platform, the company is also advancing its NeuroRestore platform, including ACD856, a clinical-stage candidate designed to improve cognition and potentially treat conditions ranging from Alzheimer’s disease to traumatic brain injury, sleep apnea, and Parkinson’s disease.

AlzeCure also has a pain-management platform called Painless, which includes ACD440, a drug candidate that has already reported positive Phase 2 results in neuropathic pain.

You can read more about AlzeCure here: https://www.alzecurepharma.se/en/